Quintiles Data Management To Conduct 200th EDC Trial

Quintiles
Transnational Corp. today announced that it has reached a significant
milestone in data management -- the 200th clinical trial using Electronic Data
Capture (EDC).


Quintiles is using EDC in a trial being conducted in the United Kingdom
for Aerovance, Inc., of Berkeley, Calif., which is studying a drug candidate
for chronic obstructive pulmonary disease. Quintiles began using EDC in 1999
and has seen the acceptance of EDC accelerate since then, with more than 60
EDC trials put into production in 2005.


"This achievement is important for Quintiles as well as the pharmaceutical
and biotechnology industries because it indicates the increasing recognition
of the tangible benefits of EDC," said Paula Brown Stafford, Executive Vice
President, Global Data Management, Quintiles. "As the leader in outsourced
EDC services, we are seeing greater appreciation for the potential savings in
time and expense, as well as the ability to provide better access to data
throughout the length of the study.


"We are thrilled to work again with Aerovance, an emerging
biopharmaceutical company that is conducting important research into serious
respiratory and inflammatory diseases. Quintiles looks forward to bringing
Aerovance our expertise managing electronic patient data."


Quintiles also is conducting EDC studies for Aerovance in the treatment of
cystic fibrosis, asthma and eczema.


"Quintiles Data Management has developed an elegant clinical EDC program
for us," said Richard Fuller, Chief Operating Officer, Aerovance. "We turned
to Quintiles because of the good experience we had working with them before,
as well as their flexibility, which allows them to work with an emerging
biotech like us just as they would with a major pharmaceutical company."


About Aerovance


Aerovance is a privately held biopharmaceutical company focused
exclusively on the development and commercialization of biologics for severe
respiratory and inflammatory diseases such as asthma, cystic fibrosis (CF),
chronic obstructive pulmonary disease (COPD) and eczema. The company's two
lead products are AER001, an IL4/13 receptor antagonist for severe asthma and
eczema currently in Phase 2 studies, and AER002 a recombinant protein for CF
and COPD currently in Phase 2 studies. In addition to these investigational
products, Aerovance has several preclinical programs in respiratory disease.
Aerovance was spun off from Bayer Pharmaceuticals' biotechnology unit in
August 2004.


About Quintiles Global Data Management


Quintiles Global Data Management delivers consistent, accurate data
through flexible and cost-effective solutions for customers. Services include
capturing, analyzing and reporting patient-related data traditionally, by
paper and fax, or electronically, by EDC and PDA, and then integrating data
into a clean, compatible and fully CDISC-compliant database to facilitate
regulatory submission and acceptance. Quintiles Global Data Management has
more than 1,000 employees in 10 offices around the world.


About Quintiles


Quintiles is the global leader in pharmaceutical services, improving
healthcare worldwide by providing innovative, quality professional expertise,
market intelligence and partnering solutions to meet the dynamic needs of the
pharmaceutical, biotechnology and healthcare industries. Quintiles has 16,000
specialized employees and offices in 50 countries. For more information visit
the company's Web site at quintiles.


Quintiles Transnational Corp.

quintiles

Buy Spiriva Online no Prescription